In the study by Nissenkorn et al. (146), 11 of 17 (65%) patients with Dravet syndrome due to an SCN1A pathogenic variant were responders, and 35% of them had >90% seizure reduction. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.